Across the recent three months, 13 analysts have shared their insights on Centene CNC, expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 9 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 4 | 0 | 0 | 0 |
| 3M Ago | 1 | 4 | 2 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.77, a high estimate of $98.00, and a low estimate of $66.00. This current average represents a 0.09% decrease from the previous average price target of $88.85.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive Centene is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Ha | Baird | Lowers | Neutral | $66.00 | $83.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $90.00 | $90.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $90.00 | $90.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $91.00 | $93.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $90.00 | $90.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $97.00 | $98.00 |
| Andrew Mok | Barclays | Raises | Overweight | $98.00 | $90.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $90.00 | $90.00 |
| Scott Fidel | Stephens & Co. | Maintains | Equal-Weight | $78.00 | $78.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $93.00 | $81.00 |
| George Hill | Deutsche Bank | Raises | Hold | $87.00 | $82.00 |
| Gary Taylor | TD Cowen | Raises | Buy | $89.00 | $80.00 |
| Michael Wiederhorn | Oppenheimer | Lowers | Outperform | $95.00 | $110.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Centene. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Centene compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Centene's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into Centene's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Centene analyst ratings.
Delving into Centene's Background
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
Unraveling the Financial Story of Centene
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 5.92%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Centene's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.88%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Centene's ROE excels beyond industry benchmarks, reaching 4.22%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Centene's ROA stands out, surpassing industry averages. With an impressive ROA of 1.38%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Centene's debt-to-equity ratio surpasses industry norms, standing at 0.64. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
